Multitarget drugs of plants origin acting on alzheimer's disease

P. Russo, A. Frustaci, A. Del Bufalo, M. Fini, A. Cesario

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The etiopathology of Alzheimer's disease (AD) is extremely complex and heterogeneous, often associated with comorbidities. As a result it may be unlikely that AD may be mitigated by drug acting on a single specific target. The current tendency in drug design and discovery in AD is the rational design or 'serendipitous' discovery of new drug entities challenging multiple targets. Since two of the presently approved drugs for AD are based on natural products (galantamine and the physostigmine-derivative rivastigmine), many plants are now under investigation as a potential source of new drugs. Multifunctional drugs often have their origin in natural sources. This review is limited to plant chemicals having different targets with actual (galantamine) or promising (drugs from Crocus sativus, Ginkgo biloba, Salvia species, and Huperzia serrata) clinical evidence in people with dementia or AD.

Original languageEnglish
Pages (from-to)1686-1693
Number of pages8
JournalCurrent Medicinal Chemistry
Volume20
Issue number13
DOIs
Publication statusPublished - Apr 2013

Fingerprint

Alzheimer Disease
Galantamine
Pharmaceutical Preparations
Rivastigmine
Drug Discovery
Huperzia
Salvia
Ginkgo biloba
Physostigmine
Drug Design
Biological Products
Dementia
Comorbidity
Chemical plants
Derivatives

Keywords

  • Alzheimer's disease
  • Cholinergic system
  • Crocus sativus
  • Drug discovery and development
  • Galantamine
  • Ginkgo biloba
  • Huperzia serrata
  • Multitargets
  • NAChR
  • Nicotine
  • Plant drug
  • Salvia species
  • Systems biology

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Multitarget drugs of plants origin acting on alzheimer's disease. / Russo, P.; Frustaci, A.; Bufalo, A. Del; Fini, M.; Cesario, A.

In: Current Medicinal Chemistry, Vol. 20, No. 13, 04.2013, p. 1686-1693.

Research output: Contribution to journalArticle

@article{671991d63470418f94783ec0c5ec9a88,
title = "Multitarget drugs of plants origin acting on alzheimer's disease",
abstract = "The etiopathology of Alzheimer's disease (AD) is extremely complex and heterogeneous, often associated with comorbidities. As a result it may be unlikely that AD may be mitigated by drug acting on a single specific target. The current tendency in drug design and discovery in AD is the rational design or 'serendipitous' discovery of new drug entities challenging multiple targets. Since two of the presently approved drugs for AD are based on natural products (galantamine and the physostigmine-derivative rivastigmine), many plants are now under investigation as a potential source of new drugs. Multifunctional drugs often have their origin in natural sources. This review is limited to plant chemicals having different targets with actual (galantamine) or promising (drugs from Crocus sativus, Ginkgo biloba, Salvia species, and Huperzia serrata) clinical evidence in people with dementia or AD.",
keywords = "Alzheimer's disease, Cholinergic system, Crocus sativus, Drug discovery and development, Galantamine, Ginkgo biloba, Huperzia serrata, Multitargets, NAChR, Nicotine, Plant drug, Salvia species, Systems biology",
author = "P. Russo and A. Frustaci and Bufalo, {A. Del} and M. Fini and A. Cesario",
year = "2013",
month = "4",
doi = "10.2174/0929867311320130008",
language = "English",
volume = "20",
pages = "1686--1693",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "13",

}

TY - JOUR

T1 - Multitarget drugs of plants origin acting on alzheimer's disease

AU - Russo, P.

AU - Frustaci, A.

AU - Bufalo, A. Del

AU - Fini, M.

AU - Cesario, A.

PY - 2013/4

Y1 - 2013/4

N2 - The etiopathology of Alzheimer's disease (AD) is extremely complex and heterogeneous, often associated with comorbidities. As a result it may be unlikely that AD may be mitigated by drug acting on a single specific target. The current tendency in drug design and discovery in AD is the rational design or 'serendipitous' discovery of new drug entities challenging multiple targets. Since two of the presently approved drugs for AD are based on natural products (galantamine and the physostigmine-derivative rivastigmine), many plants are now under investigation as a potential source of new drugs. Multifunctional drugs often have their origin in natural sources. This review is limited to plant chemicals having different targets with actual (galantamine) or promising (drugs from Crocus sativus, Ginkgo biloba, Salvia species, and Huperzia serrata) clinical evidence in people with dementia or AD.

AB - The etiopathology of Alzheimer's disease (AD) is extremely complex and heterogeneous, often associated with comorbidities. As a result it may be unlikely that AD may be mitigated by drug acting on a single specific target. The current tendency in drug design and discovery in AD is the rational design or 'serendipitous' discovery of new drug entities challenging multiple targets. Since two of the presently approved drugs for AD are based on natural products (galantamine and the physostigmine-derivative rivastigmine), many plants are now under investigation as a potential source of new drugs. Multifunctional drugs often have their origin in natural sources. This review is limited to plant chemicals having different targets with actual (galantamine) or promising (drugs from Crocus sativus, Ginkgo biloba, Salvia species, and Huperzia serrata) clinical evidence in people with dementia or AD.

KW - Alzheimer's disease

KW - Cholinergic system

KW - Crocus sativus

KW - Drug discovery and development

KW - Galantamine

KW - Ginkgo biloba

KW - Huperzia serrata

KW - Multitargets

KW - NAChR

KW - Nicotine

KW - Plant drug

KW - Salvia species

KW - Systems biology

UR - http://www.scopus.com/inward/record.url?scp=84877962244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877962244&partnerID=8YFLogxK

U2 - 10.2174/0929867311320130008

DO - 10.2174/0929867311320130008

M3 - Article

C2 - 23410167

AN - SCOPUS:84877962244

VL - 20

SP - 1686

EP - 1693

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 13

ER -